
Humacyte (HUMA) Stock Forecast & Price Target
Humacyte (HUMA) Analyst Ratings
Bulls say
Humacyte is a pre-commercial clinical development-stage biotechnology company with a positive outlook due to the potential launch of Acellular Tissue Engineered Vessels (ATEV) in dialysis access in 2027 and a diverse pipeline targeting a range of diseases. The recent approval of its V012 clinical trial results by the FDA increases the probability of success for ATEV, and the company's strategic partnerships and financial backing provide further support for its future success.
Bears say
Humacyte is currently facing challenges in gaining sales traction and gaining regulatory approvals for their products, leading to continued operating losses and the need for additional financing. In addition, the unpredictable regulatory environment and potential product failures add to the overall investment risk.
This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.
Humacyte (HUMA) Analyst Forecast & Price Prediction
Start investing in Humacyte (HUMA)
Order type
Buy in
Order amount
Est. shares
0 shares